U.S. Professional Services Stock News

Ardelyx (ARDX) has drawn fresh attention after securing a new US patent that extends protection for its tenapanor formulations, IBSRELA and XPHOZAH, to 2042, while also advancing IBSRELA into a Phase 3 trial in chronic idiopathic constipation. See our latest analysis for Ardelyx. Ardelyx’s recent patent win and progress with the ACCEL Phase 3 trial come after a strong run, with a 30-day share price return of 25.85% and a 1-year total shareholder return of 40.22%, alongside a small pullback...

Labcorp Holdings (NYSE:LH) has amended its receivables purchase agreement, extending the facility’s termination date. The amendment adds an accordion feature that can increase borrowing capacity under certain conditions. The revised structure is intended to provide greater liquidity flexibility for the company’s operations and planning. Labcorp is a large diagnostics and laboratory services provider, so reliable access to funding is important for supporting day to day testing volumes and...

Why Central Bancompany is on investors’ radar today Central Bancompany (CBC) is drawing attention after a recent move in its share price, with the stock closing at $24.50 and showing varied returns over the past day, week, month, and past 3 months. See our latest analysis for Central Bancompany. While the 1 day share price return shows a 1.61% pullback to $24.50, the 90 day share price return of 15.29% sits alongside a 1 year total shareholder return of 89.00%. Together, these figures point...

If you are wondering whether WeRide's current share price offers value or just fresh risk, you are not alone. This article is going to focus squarely on what the numbers are saying about its valuation. WeRide's shares last closed at US$7.58, with returns of 14.3% decline over the past week, 19.3% decline over the past month, and 48.0% decline over the last year. This raises fair questions about how the market is currently pricing the stock. Recent news around autonomous driving regulation,...

If you are wondering whether Five9's current share price reflects its true worth, you are not alone. This article will walk through the key numbers that matter for valuation. Five9's share price closed at US$16.71, with returns of a 9% decline over 7 days, an 11.2% decline over 30 days, an 11.2% decline year to date, a 60.8% decline over 1 year, an 80.2% decline over 3 years and a 90.6% decline over 5 years, which naturally raises questions about both risk and potential. Recent coverage has...

If you are wondering whether UniFirst at around US$203 is a fair deal or a stretch, you are not alone. This article is built to help you frame that question clearly. The stock has seen mixed returns, with a 4.9% gain over the past month and year to date, against a 3.2% decline over the last 7 days and an 8% decline over the past year. These moves may have shifted how some investors view its potential and risks. Recent coverage around UniFirst has largely focused on the company as a long...

Alphabet recently moved to dramatically expand its footprint in India, securing rights to up to 2.4 million square feet of office space in Bengaluru that could house as many as 20,000 additional employees, while its Waymo unit raised US$16 billion at a US$126 billion valuation and investors looked ahead to Q4 2025 earnings. Together, the India build-out, Waymo funding, and Gemini- and cloud-focused expectations highlight how Alphabet is tying long-term AI and autonomous-mobility ambitions to...

If you are wondering whether Guardant Health at US$113.05 is starting to look expensive or still offers value, you are not alone in asking that question right now. The stock has seen a 1.3% decline over the last 7 days, an 11.1% return over the last 30 days and year to date, a 139.7% return over the last year, a 295.8% return over 3 years, and a 30.8% decline over 5 years. This may suggest the market’s view of its risk and potential has shifted over different time frames. Recent coverage has...

Tencent Music Entertainment Group (NYSE:TME) has formed a new joint venture called ONECEAD with CJ ENM and JYP China. The partnership focuses on developing, launching and managing next generation artists for global audiences. ONECEAD is intended to combine music production, artist management and content distribution capabilities across China, Korea and international markets. For investors watching NYSE:TME, this move comes with the stock at $16.4 and a 1 year return of 38.2%. Over 3 years,...

Coty recently announced a collaboration with OpenAI to roll out ChatGPT Enterprise across selected parts of its global organization, aiming to support employees’ daily work, creativity and cross‑functional collaboration with enterprise-grade AI tools. This move positions Coty as an early adopter of advanced AI within the beauty industry, potentially reshaping how it manages innovation, efficiency and internal decision-making. We will now examine how Coty’s adoption of ChatGPT Enterprise...

If you are wondering whether Horace Mann Educators at around US$44.92 still offers value, an important question is how its current price compares with what the business may be worth. The stock has returned 4.7% over the last 7 days, while the 1 year return sits at 21.7% and the 3 year return at 38.6%. A 0.6% decline year to date may suggest that expectations and risk perceptions are changing. Recent coverage has focused on Horace Mann Educators as an insurer serving the education community,...

Key Insights The considerable ownership by private companies in GDEV indicates that they collectively have a greater...

Key Insights The considerable ownership by individual investors in NovaBridge Biosciences indicates that they...

To the annoyance of some shareholders, Nocera, Inc. ( NASDAQ:NCRA ) shares are down a considerable 37% in the last...

Some AZZ Inc. ( NYSE:AZZ ) shareholders may be a little concerned to see that the President, Thomas Ferguson, recently...

One thing we could say about the analysts on Aquestive Therapeutics, Inc. ( NASDAQ:AQST ) - they aren't optimistic...

Seadrill (NYSE:SDRL) is being discussed as a potential acquisition target, with management indicating openness to a sale at a premium. The company has announced several significant contract wins and extensions for its ultra deepwater fleet. These new contracts add to Seadrill's revenue backlog and provide increased visibility on future operations. The combination of M&A interest and fresh contract activity is drawing attention to Seadrill's position in the offshore drilling...

If you are wondering whether Simon Property Group's current share price reflects its true value, you are not alone. This article will help you connect the recent share performance with what the fundamentals may be pointing to. At a last close of US$189.42, the stock has returns of 2.6% over the past 7 days, 3.0% over the past 30 days, 3.0% year to date, 14.8% over 1 year and 141.0% over 5 years, which naturally raises questions about how much of this is already priced in. Recent attention on...

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

Sagimet Biosciences recently reported that Ascletis Pharma’s Phase 3 trial of ASC40 (Denifanstat) for acne met all primary and secondary endpoints and was well-tolerated, with no serious adverse events observed. The results highlight fatty acid synthase (FASN) inhibition as a potentially new way to treat acne, with findings slated for presentation at upcoming medical congresses and in scientific publications. Next, we’ll examine how Denifanstat’s Phase 3 success in acne may influence Sagimet...

This article walks through key signals you can use to assess whether Under Armour at around US$6.24 might be a bargain or a value trap. The stock is up 18.0% over the last month and 18.0% year to date, while the 1-year return of negative 24.4% and 3- and 5-year returns of negative 48.9% and negative 69.9% highlight a much tougher longer-term picture. Recent attention on Under Armour has focused on how the brand fits into an increasingly competitive athletic apparel market and what that could...

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

If you are wondering whether Wintrust Financial's recent share price leaves much upside on the table, it starts with understanding what the current market price is really implying about the bank's long term prospects. The stock last closed at US$156.04, with returns of 7.3% over the past week, 9.4% over the past month, 9.4% year to date and 22.8% over the past year. The 3 year and 5 year returns sit at 72.2% and 149.7% respectively. These returns have helped put Wintrust Financial on the...

If you are wondering whether U.S. Bancorp's share price still offers value after a solid run, this article walks through what the current market price could be implying about the business. With the stock last closing at US$58.69, U.S. Bancorp has recorded returns of 3.8% over 7 days, 8.8% over 30 days, 8.8% year to date, 29.1% over 1 year, 36.3% over 3 years, and 52.7% over 5 years. Recent coverage of large U.S. banks has focused on how they are positioned under current interest rate...